Clinical Trial Update: Improving the Outcome of High-risk Aggressive B-cell Lymphoma Patients With Nivolumab Maintenance Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial exploring nivolumab maintenance therapy to improve outcomes in high-risk aggressive B-cell lymphoma patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma B-cell

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Meirav Kedmi MD | Conditions: Lymphoma, B-Cell | Phase 2 | Status: UNKNOWN